Søren Thinggaard Hansen has joined Denmark-based pharmaceutical firm Novo as a senior partner to set up a private equity initiative to complement its existing corporate venturing strategy.
Hansen had previously spent more than 17 years at local pension fund Industriens Pension, mainly as head of private equity.
Novo already provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies within life science through a public corporate venturing strategy.
The Novo Holdings Repair Impact Fund also has an investment proposal to life sciences companies developing new treatments to combat anti-microbial resistance.
